The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly O.
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
 
Kazuomi Ueshima
Honoraria - Abbvie; AstraZeneca; Asuka Seiyaku; Bayer; Chugai Pharma; EA Pharma; Eisai; Kowa; Lilly Japan; MSD; Otsuka; Sumitomo Dainippon Pharma; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Lilly Japan; Pfizer; Takeda
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); EA Pharma (Inst); Eisai (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Kaoru Tsuchiya
Consulting or Advisory Role - Chugai Pharma; Eisai
Speakers' Bureau - Chugai Pharma; Eisai; Lilly Japan; Takeda
 
Naoya Kato
Speakers' Bureau - Abbott; Abbvie; Aska Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb Company; Chugai Pharma; Covidien; Daiichi Sankyo Co.,Ltd.; EA Pharma; Eisai; Fujifilm; Gilead Sciences; Kowa; Lilly Japan; Mitsubishi Tanabe Pharma; Miyarisan pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Mylan; Nichi-iko; Nippon Kayaku; Nobelpharma; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Takeda; Tsumura & Co.; Zeria Pharmaceutical
Research Funding - Abbvie (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Aska Pharmaceutical Co.,Ltd. (Inst); Astellas Pharma (Inst); Boston Scientific (Inst); Chugai Pharma (Inst); Covidien (Inst); CYTLIMIC (Inst); Daiichi Sankyo co.,Ltd. (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); JIMRO (Inst); Kowa (Inst); Medicos Hirata (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Shionogi (Inst); Sumitomo Dainippon Pharma Co.,Ltd. (Inst); Takeda (Inst); Tsumura & Co. (Inst)
 
Tatsuya Yamashita
Speakers' Bureau - Bayer; Chugai Pharma; Eisai; Lilly; Takeda
 
Shigeo Shimose
No Relationships to Disclose
 
Kazushi Numata
No Relationships to Disclose
 
Yuzo Kodama
No Relationships to Disclose
 
Yasuhito Tanaka
No Relationships to Disclose
 
Hidekatsu Kuroda
No Relationships to Disclose
 
Shinji Itoh
No Relationships to Disclose
 
Hiroshi Aikata
No Relationships to Disclose
 
Atsushi Hiraoka
No Relationships to Disclose
 
Michihisa Moriguchi
Research Funding - Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst)
 
Yoshiyuki Wada
No Relationships to Disclose
 
Kazuhiko Nakao
No Relationships to Disclose
 
Ryosuke Tateishi
Honoraria - Abbvie; AstraZeneca; Bayer Yakuhin; Daiichi Sankyo; Eisai; Fujifilm; Gilead Sciences; Merck Sharp & Dohme; Shionogi; Sumitomo Dainippon
Consulting or Advisory Role - Bayer Yakuhin
Research Funding - Wako Diagnostics
 
Sadahisa Ogasawara
No Relationships to Disclose
 
Kouji Yamamoto
Honoraria - Chugai Pharma; CM Plus; CMIC Co., Ltd.; J-Pharma; Johokiko; Sysmex; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Kyowa Kirin International (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Chugai Pharma; Eisai; Lilly Japan; MSD; Novartis; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)